Annie Martin, SVP, Global Head of Precision Medicine at Novartis Bio and Contact Info
Joydeep Goswami, President of Clinical Next Generation Sequencing and Oncology at Thermo Fisher Bio and Contact Info
Hakan Sakul, VP of Diagnostics at Pfizer Bio and Contact Info
0:00 What does this approval mean for patients?
3:08 How did this come about?
6:03 A first for the FDA and partners
8:02 How is this different from what we did before?
11:28 Panel vs whole genome
18:20 Other cancers?
21:03 How did you pull this off?
Today we get to bring you a feel good story, one of the major achievements so far in precision oncology. Three large companies—Thermo Fisher, Pfizer, and Novartis—put aside their differences to come together for patients.
The patients are those who suffer from non-small cell lung cancer. In June, the FDA approved for the first time an NGS panel with multiple genes for multiple drugs that treat this kind of cancer.
“It’s groundbreaking for patients, because instead of having to wait for a hierarchal testing approach to their cancer, this one test could be able to give the answer for the patient."
By hierarchical, Annie Martin, the VP Global Head of Precision Medicine at Novartis, means the usual stepwise approach to testing for patients with this cancer. Typically patients are tested for first EGFR, followed by ALK, followed by ROS1, followed by BRAF. Now, thanks to a new NGS panel out by Thermo, all of these tests will be done at once and has been approved for various therapies.
In addition to Annie, we’re also joined by Thermo’s Joydeep Goswami, President of Clinical Next Generation Sequencing and Oncology at Thermo Fisher and by Hakan Sakul, VP of Diagnostics at Pfizer to talk about their collaboration.
How did Thermo decide on this panel, and what possible future uses to do they see? And how did the three large corporations—one diagnostics and two pharmas--come together to pull this off?
Join us with three of the industry’s leaders as we uncover the work behind a major milestone for precision oncology.